Search Results

You are looking at 1 - 2 of 2 items for

  • Author: Tsvetan H. Lukanov x
Clear All Modify Search
Open access

Ginka H. Rayanova, Silvia S. Ganeva, Katya N. Todorova, Tsvetan H. Lukanov and Svetla P. Gecheva

Summary

The aim of the study is to investigate the serum levels of adipokines-resistin and visfatin in patients with metabolic syndrome. A prospective study was performed, including 153 (103 female, 50 male) subjects with metabolic syndrome. Carbohydrate metabolism was estimated by oral glucose tolerance test with 75g of glucose. Of the subjects investigated, 40 were with normal glycaemic tolerance, 40 - with impaired fasting glycaemia, 28 - with impaired glucose tolerance and 45 - with newly diagnosed diabetes mellitus type 2. The results were compared to those in a control group of 20 subjects without findings indicating metabolic syndrome. The serum levels of resistin and visfatin were measured with an enzyme immunoassay method (ELISA, BioVendor Laboratory Medicine, Inc., Czech Republic). There were significant differences in body mass index, waist circumference, systolic blood pressure, plasma level of blood glucose and serum level of triglycerides between the examined subjects with metabolic syndrome, as compared with the control group. The amount of serum resistin in subjects with metabolic syndrome and newly diagnosed diabetes mellitus type 2 was significantly higher, as compared to the controls. Subjects with metabolic syndrome and pathological glucose tolerance-impaired fasting glycaemia, impaired glucose tolerance and newly diagnosed diabetes mellitus type 2 were found with a significantly higher serum level of visfatin, as compared to normal glucose tolerance and to the controls. Subjects with metabolic syndrome and pathological glucose tolerance-impaired fasting glucose, impaired glucose tolerance and newly diagnosed diabetes mellitus type 2 exhibited significantly changes in serum levels of adipokines-resistin and visfatin.

Open access

Vanya S. Popova, Svetla O. Blajeva, Margarita L. Alexandrova, Tsvetan H. Lukanov, Silvia Y. Naneva and Nikolay T. Tzvetkov

Summary

Chronic lymphocytic leukemia is one of the most common types of leukemia in adults. It belongs to the group of indolent lymphoproliferative disorders and has a slow clinical course. Approximately 50% of newly diagnosed patients do not require treatment for years. A better understanding of the pathophysiology of the disease has led to the development of models for assessment of the risk.

Our study aimed to evaluate the prognostic significance of the serum marker beta-2 microglobulin (82M) and the flow cytometric marker CD49d in patients with early-stage of B-chronic lymphocytic leukemia (B-CLL) as well as look for a correlation between CD 49d and the early stages of the disease. For this purpose, analysis of 30 untreated patients with known and newly diagnosed B-CLL was carried out. The following methods were used: documentary, flow cytometric analysis of peripheral blood, Rai staging system and chi-square test of independence (Fisher’s Exact Test). The results from our study showed that a small number of patients in the early stage of the disease have high levels of CD49d expression and beta-2 microglobulins. In eight of 29 patients, the flow cytometric marker was higher than 30%, and in ten out of 29 patients, the B2M was above the reference range. No significant correlation between the two markers in early stage B-CLL patients was found.